Generate Investment Management Ltd Buys New Position in Repligen Corporation $RGEN

Generate Investment Management Ltd acquired a new position in Repligen Corporation (NASDAQ:RGEN) in the 1st quarter, Holdings Channel.com reports. The firm acquired 41,521 shares of the biotechnology company’s stock, valued at approximately $4,892,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. NewEdge Wealth LLC boosted its position in shares of Repligen by 5.3% in the fourth quarter. NewEdge Wealth LLC now owns 1,492 shares of the biotechnology company’s stock worth $244,000 after purchasing an additional 75 shares during the period. UMB Bank n.a. raised its position in shares of Repligen by 13.8% during the 4th quarter. UMB Bank n.a. now owns 758 shares of the biotechnology company’s stock valued at $124,000 after purchasing an additional 92 shares during the period. CANADA LIFE ASSURANCE Co lifted its stake in shares of Repligen by 0.3% during the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 36,599 shares of the biotechnology company’s stock valued at $4,542,000 after buying an additional 100 shares in the last quarter. Coldstream Capital Management Inc. lifted its stake in shares of Repligen by 5.3% during the 4th quarter. Coldstream Capital Management Inc. now owns 1,992 shares of the biotechnology company’s stock valued at $326,000 after buying an additional 101 shares in the last quarter. Finally, Itau Unibanco Holding S.A. boosted its holdings in Repligen by 38.0% in the 4th quarter. Itau Unibanco Holding S.A. now owns 378 shares of the biotechnology company’s stock worth $62,000 after buying an additional 104 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.

Repligen Stock Down 4.1%

RGEN opened at $126.57 on Tuesday. The firm has a 50-day simple moving average of $121.81 and a two-hundred day simple moving average of $136.08. Repligen Corporation has a 52 week low of $100.99 and a 52 week high of $175.77. The company has a market capitalization of $7.14 billion, a PE ratio of 140.63, a price-to-earnings-growth ratio of 2.54 and a beta of 1.09. The company has a quick ratio of 7.78, a current ratio of 9.20 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share for the quarter, beating analysts’ consensus estimates of $0.38 by $0.10. Repligen had a return on equity of 4.88% and a net margin of 6.73%.The firm had revenue of $194.25 million during the quarter, compared to analyst estimates of $192.05 million. During the same quarter last year, the business posted $0.39 earnings per share. The business’s quarterly revenue was up 14.8% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. Analysts forecast that Repligen Corporation will post 1.99 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. KeyCorp reaffirmed an “overweight” rating on shares of Repligen in a research note on Wednesday, February 25th. Royal Bank Of Canada initiated coverage on Repligen in a research note on Thursday, May 14th. They set an “outperform” rating and a $160.00 target price on the stock. Weiss Ratings raised Repligen from a “sell (d)” rating to a “sell (d+)” rating in a report on Thursday, May 7th. Roth Mkm began coverage on Repligen in a research note on Friday, April 17th. They issued a “buy” rating and a $160.00 price target for the company. Finally, HC Wainwright increased their price objective on shares of Repligen from $180.00 to $208.00 and gave the company a “buy” rating in a report on Monday, March 23rd. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $164.64.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.